US006387397B1

(12) **United States Patent**
Chen et al.

(10) **Patent No.: US 6,387,397 B1**
(45) **Date of Patent: May 14, 2002**

(54) **POLYMERIZED LIPOSOMES TARGETED TO M CELLS AND USEFUL FOR ORAL OR MUCOSAL DRUG DELIVERY**

(75) Inventors: **Hongming Chen**, Lansdale, PA (US); **Robert S. Langer**, Newton, MA (US)

(73) Assignee: **Massachusetts Institute of Technology**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/324,458**

(22) Filed: **Jun. 2, 1999**

Related U.S. Application Data

(62) Division of application No. 08/844,138, filed on Apr. 18, 1997, now Pat. No. 6,060,082.

(51) **Int. Cl.**[7] **A61K 9/127**
(52) **U.S. Cl.** **424/450**; 436/829; 428/402.2
(58) **Field of Search** 424/450, 812, 424/1.21, 9.321, 9.51, 417; 436/829; 935/54; 428/402.2

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,201,767	A	5/1980	Fullerton et al.
4,229,360	A	10/1980	Schneider et al.
4,248,829	A	2/1981	Kitajima et al.
4,348,329	A	9/1982	Chapman
4,429,008	A	1/1984	Martin et al.
4,485,045	A	11/1984	Regen
4,522,811	A	6/1985	Eppstein et al.
4,544,545	A	10/1985	Ryan et al.
4,560,599	A	12/1985	Regen
4,564,475	A	1/1986	Masaichiro
4,574,193	A	3/1986	Arnold et al.
4,587,055	A	5/1986	Regen
4,594,193	A	6/1986	Regen

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

EP	0333523		9/1989
JP	60-081192		5/1985
WO	WO 90/06430		11/1990
WO	WO 90/06433		11/1990
WO	WO 92/04009		3/1992
WO	WO 92/13447		8/1992
WO	WO 93/10763		6/1993
WO	WO 95/03035		2/1995
WO	95/03035	*	2/1995
WO	WO 95/04524		2/1995
WO	WO 96/13250		5/1996

OTHER PUBLICATIONS

Wassef in Immunomethods 4; 217–222, 1996.*

Chen in Proc. Int. Symp. controlled release Bioach Mater. 22: 204–205, 1995.*

Russell–Jones, J Exbtl. Medicine 167, p. 440–451, 1986.*

Neutral Tissue Res. 247, p. 537, 1987.*

Anderson et al., 1994, "Cytokines in Liposomes: Preliminary Studies with IL–1, IL–2, IL–6, GM–CSF and Interferon–y", Cytokine 6:92–101.

Aramaki et al., 1994, "Activation of Systemic and Mucosal Immune Response Following Nasal Administration of Liposomes", Vaccine 12:1241–1245.

(List continued on next page.)

Primary Examiner—Gollamudi S. Kishore
(74) *Attorney, Agent, or Firm*—Pennie & Edmonds LLP

(57) **ABSTRACT**

The present invention relates to targeted polymerized liposomes for oral and/or mucosal delivery of vaccines, allergens and therapeutics. In particular, the present invention relates to polymerized liposomes which have been modified on their surface to contain a molecule or ligand which targets the polymerized liposome to a specific site or cell type. More particularly, the invention relates to the use of polymerized liposomes modified to contain a carbohydrate or lectin on their surface.

37 Claims, 9 Drawing Sheets